177 related articles for article (PubMed ID: 12137406)
1. Pexelizumab Alexion.
Whiss PA
Curr Opin Investig Drugs; 2002 Jun; 3(6):870-7. PubMed ID: 12137406
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab (Alexion).
Kaplan M
Curr Opin Investig Drugs; 2002 Jul; 3(7):1017-23. PubMed ID: 12186261
[TBL] [Abstract][Full Text] [Related]
3. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
[TBL] [Abstract][Full Text] [Related]
4. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
[TBL] [Abstract][Full Text] [Related]
5. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
Mahaffey KW; Van de Werf F; Shernan SK; Granger CB; Verrier ED; Filloon TG; Todaro TG; Adams PX; Levy JH; Hasselblad V; Armstrong PW
Am Heart J; 2006 Aug; 152(2):291-6. PubMed ID: 16875911
[TBL] [Abstract][Full Text] [Related]
6. TP-10 (AVANT Immunotherapeutics).
Rioux P
Curr Opin Investig Drugs; 2001 Mar; 2(3):364-71. PubMed ID: 11575706
[TBL] [Abstract][Full Text] [Related]
7. Ximelagatran (AstraZeneca).
Hopfner R
Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
[TBL] [Abstract][Full Text] [Related]
9. Etanercept. Immunex.
Pugsley MK
Curr Opin Investig Drugs; 2001 Dec; 2(12):1725-31. PubMed ID: 11892935
[TBL] [Abstract][Full Text] [Related]
10. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
Fleisig AJ; Verrier ED
Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
[TBL] [Abstract][Full Text] [Related]
11. Valdecoxib (Pharmacia).
Gotta AW
Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
[TBL] [Abstract][Full Text] [Related]
12. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
[TBL] [Abstract][Full Text] [Related]
13. Cariporide Aventis.
Chin B; Lip GY
Curr Opin Investig Drugs; 2000 Nov; 1(3):340-6. PubMed ID: 11249717
[TBL] [Abstract][Full Text] [Related]
14. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
Patel JA; Ghatak SB
Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):145-52. PubMed ID: 18537766
[TBL] [Abstract][Full Text] [Related]
15. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
Smith PK; Shernan SK; Chen JC; Carrier M; Verrier ED; Adams PX; Todaro TG; Muhlbaier LH; Levy JH;
J Thorac Cardiovasc Surg; 2011 Jul; 142(1):89-98. PubMed ID: 20880552
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery.
Chen JC; Rollins SA; Shernan SK; Boyce S; Allen K; Wallace A; Malloy KJ; Eng JS; Colman RW; Fitch JC;
J Card Surg; 2005; 20(1):35-41. PubMed ID: 15673408
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
Fitch JC; Rollins S; Matis L; Alford B; Aranki S; Collard CD; Dewar M; Elefteriades J; Hines R; Kopf G; Kraker P; Li L; O'Hara R; Rinder C; Rinder H; Shaw R; Smith B; Stahl G; Shernan SK
Circulation; 1999 Dec 21-28; 100(25):2499-506. PubMed ID: 10604887
[TBL] [Abstract][Full Text] [Related]
18. MethyPatch Noven.
Sane N; McGough JJ
Curr Opin Investig Drugs; 2002 Aug; 3(8):1222-4. PubMed ID: 12211419
[TBL] [Abstract][Full Text] [Related]
19. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
Haverich A; Shernan SK; Levy JH; Chen JC; Carrier M; Taylor KM; Van de Werf F; Newman MF; Adams PX; Todaro TG; van der Laan M; Verrier ED
Ann Thorac Surg; 2006 Aug; 82(2):486-92. PubMed ID: 16863750
[TBL] [Abstract][Full Text] [Related]
20. Thymitaq (Zarix).
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
